NYSE · EW
Healthcare · Medical - Devices
$85.74
Up+$0.22 (+0.26%)
Updated Sep 16, 2026, 10:29 AM
SID Score
6.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EW closed at $85.74 after 20 trading sessions, down 5.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $85.03 | $86.025 | $84.47 | $85.74 | 3.78M |
| Sep 14, 2026 | $85.45 | $86.26 | $85.12 | $85.52 | 2.99M |
| Sep 11, 2026 | $87.51 | $87.755 | $83.81 | $84.37 | 3.8M |
| Sep 10, 2026 | $86.00 | $87.27 | $85.00 | $86.77 | 2.31M |
| Sep 9, 2026 | $86.27 | $87.04 | $85.73 | $86.18 | 2.74M |
| Sep 8, 2026 | $89.07 | $89.095 | $86.39 | $86.72 | 3.58M |
| Sep 4, 2026 | $90.21 | $90.21 | $88.40 | $89.90 | 2.64M |
| Sep 3, 2026 | $91.08 | $91.53 | $89.33 | $89.78 | 1.84M |
| Sep 2, 2026 | $91.465 | $92.3568 | $90.55 | $90.82 | 2.6M |
| Sep 1, 2026 | $91.39 | $92.95 | $90.10 | $90.74 | 2.54M |
| Aug 31, 2026 | $91.00 | $91.29 | $89.315 | $90.75 | 4.05M |
| Aug 28, 2026 | $89.98 | $90.4099 | $89.55 | $90.21 | 2.04M |
| Aug 27, 2026 | $90.78 | $91.48 | $89.79 | $89.95 | 3.06M |
| Aug 26, 2026 | $90.29 | $92.12 | $90.08 | $90.78 | 2.78M |
| Aug 25, 2026 | $90.38 | $91.265 | $89.68 | $90.87 | 2.39M |
| Aug 24, 2026 | $89.885 | $91.11 | $89.46 | $90.50 | 2.72M |
| Aug 21, 2026 | $89.89 | $90.37 | $88.79 | $89.79 | 2.82M |
| Aug 20, 2026 | $91.61 | $92.27 | $89.75 | $89.83 | 2.64M |
| Aug 19, 2026 | $91.47 | $93.25 | $91.265 | $92.28 | 3.41M |
| Aug 18, 2026 | $90.96 | $91.685 | $90.40 | $90.98 | 2.76M |
The latest Smart Investors Daily articles mentioning EW.
EW research
Company profile and research snapshot.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | BTIG | Buy | — |
| Jul 24, 2026 | Leerink Partners | Outperform | — |
| Jul 24, 2026 | Piper Sandler | Overweight | — |
| Jul 24, 2026 | JP Morgan | Overweight | — |
| Jul 16, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.
Benzinga · Sep 11, 2026
BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.
Yahoo · Sep 10, 2026
IRVINE, Calif., September 10, 2026--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):
Yahoo · Sep 8, 2026
Despite lagging behind the Dow over the past 12 months, Edwards Lifesciences continues to receive a highly bullish outlook from Wall Street analysts.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EW.
